Guenther Reiter - Epigenomics AG Insider

Epigenomics AG -- USA Stock  

USD 5.65  0.00  0.00%

Member of the Supervisory Board

Prof. Dr. Guenther Reiter is Vice Chairman of the Supervisory Board of Epigenomics AG since November 5, 2014. He was Member of the Supervisory Board since June 28, 2005. He held several managing positions such as Manager Business Administration and Controlling at Trumpf GmbH Co. in Ditzingen and at last as Executive Member of the Hofkammer of Wuerttemberg. As a Dean and Prodean, Prof. Reiter was actively involved in the development of the European School of Business in Reutlingen as Professor. Furthermore, Prof. Dr. Reiter is Member of the Supervisory Board Deltoton GmbH. He graduated from Universitaet Tuebingen in Mathematics and in Business Economics.
Age: 61  Executive Since 2014      
49 30 243 450

Management Efficiency

The company has return on total asset (ROA) of (44.29) % which means that it has lost $44.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (122.69) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 607.04 K in total debt with debt to equity ratio (D/E) of 5.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Epigenomics AG has Current Ratio of 1.92 which is within standard range for the sector.

Similar Executives

Entity Summary

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG (EPGNF) is traded on OTC Market in USA. It is located in Berlin, and employs 43 people.

Did you try this?

Run Insider Screener Now

Insider Screener

Find insiders across different sectors to evaluate their impact on performance
Hide  View All  Next  Launch Insider Screener
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Epigenomics AG to your portfolio

Top Management

Epigenomics AG Leadership Team
Albert Weber, SVP
Antje Zeise, Executive
Guenther Reiter, Executive
Gregory Hamilton, CEO, MBA
Ann Kessler, Executive
Heino Prondzynski, Chairman
Thomas Taapken, CEO
Annett Dietrich, Executive
Noel Doheny, CEO
Nicola HennebergBusse, President
Uwe Staub, COO, Ph.D
Peter Vogt, Executive

Stock Performance

Epigenomics AG Performance Indicators
Return On Equity(122.69) %
Return On Asset(44.29) %
Operating Margin(418.57) %
Current Valuation104.35 M
Price to Earning(8.47) times
Price to Book11.08 times
Price to Sales39.6 times
Revenue3.16 M
Gross Profit1000 K
EBITDA(13.22 M)